Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.35 |
| ▸ | VHL | P40337 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21470681 | 0.95 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095316 | 0.95 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL21461991 | 0.95 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL25634793 | 0.93 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9CYP46A1VHL | |
| SCHEMBL25634791 | 0.91 | NAMPT (0.54) | NAMPTCYP3A4CYP2C9CYP46A1VHL | |
| SCHEMBL21462035 | 0.88 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095375 | 0.88 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095432 | 0.88 | NAMPT (0.45) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095622 | 0.87 | NAMPT (0.43) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095312 | 0.86 | NAMPT (0.48) | NAMPTCYP3A4CYP2C9VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4132588-A1 | CHARGE VARIANT LINKERS | Seagen Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SSB, UACA, CDA | NAMPT 801/4885CYP3A4 4396/4885CYP2C9 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.